Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a biotech firm targeting aging-related diseases, successfully passed all resolutions at its Annual General Meeting. The company, known for its innovative gene therapies such as GF-1002, is gearing up for a pivotal clinical trial in 2025 to address chronic liver disease, a condition currently lacking effective treatments. Genflow’s commitment to extending healthy lifespans positions it as a potential leader in the longevity research arena.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
